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Abstract
Viral infections have gained great attention following the rapid emergence of the severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) pandemic around the globe. Even with the continuous research on developing vaccines 
and antiviral agents against various viral infections, no specific treatment or vaccine has been approved for many 
enteric or respiratory viral infections; in addition, the efficiency of currently available treatments is still limited. One 
of the most reliable and recommended strategies to control viral infections is prevention. Recently, intense studies 
are focusing on a promising approach for treating/preventing various viral infections using probiotics. As per the 
World Health Organization (WHO), probiotics can be defined as “live microorganisms which, when administered 
in adequate amount, confer a health benefit to the host.” The use of probiotics is a simple, cost-effective, and 
safe strategy to prevent viral infections, specifically; respiratory tract and intestinal ones, by different means such 
as stimulating the host’s immune response or modulating gut microbiota. In this rapid review, we emphasize the 
protective effects of probiotics against viral infections and proposed mechanisms for protection that might offer a 
novel and cost-effective treatment against current and newly discovered viruses like SARS-CoV-2.
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Introduction
The first scientific evidence regarding probiotics 
was made by Nobel laureate Metchnikoff, who sensed 
that the intake of non-pathogenic bacteria with yogurt 
had a positive influence on endogenous bacterial flora 
and gastrointestinal tract’s functionality [1]. The term 
“probiotics” was first used in 1953 by Werner Kollath 
to describe inorganic and organic supplements of 
several foods used to improve the health of malnutrition 
patients [2]. In 1965, Lilly and Stillwell used the term 
“probiotics” to describe microorganisms that promote 
other microbial growth [3]. Later, FAO/WHO has 
defined probiotics as “live microorganisms which, 
when administered in adequate amount, confer a 
health benefit to the host [4].” Figure 1 illustrates some 
beneficial effects of probiotics on human health.
To be classified as a probiotic, the microorganism 
should have certain characteristics, such as having 
a human origin source, being non-pathogenic, being 
resistant to the intestinal environment, and having a 
beneficial effect on the immune system. The majority of 
the probiotic microorganisms are “generally recognized 
as safe, GRAS” [6]. Most lactic acid bacteria (LAB) and 
bifidobacteria have been described as probiotics [7], [8]. 
However, the most common probiotic microorganisms 
are listed in Table 1.
In addition to their important biological 
activities, the probiotics were previously defined to 
have antiviral activities. Ang et al. [38] have confirmed 
in this context that Lactobacillus reuteri is capable of 
protecting human skeletal muscles and colonic cell line 
against Coxsackievirus A and Enterovirus 71 infections. 
In addition, Galán et al. [39] have proven the antiviral 
activity of Lactobacillus casei and Bifidobacterium 
adolescentis against rotavirus infection. Moreover, 
Bacillus subtilis anti-influenza activity and Lactobacillus 
gasseri anti-respiratory sentential virus potential have 
also been proved by Starosila et al. and Eguchi et al., 
respectively. However, many other studies are being 
conducted to investigate the efficacy of probiotics 
against certain viral infections.
At the end of the year 2019, an etiological 
agent responsible for the outbreak of viral pneumonia 
was detected in Wuhan, Hubei Province, China, 
and spread rapidly around the world. Then, this new 
virus was named by the International Committee on 
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Taxonomy of Viruses as severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2), causing 
coronavirus disease 19 (COVID-19) [42]. SARS-
CoV-2 belongs to the Orthocoronavirinae subfamily 
of the Coronaviridae family in the order Nidovirales. 
Coronaviruses named after the distribution of crown-
like spikes on the outer surface of the virus particle. In 
addition, the nucleic material of these viruses is a single-
stranded, positive-sensing RNA (+ssRNA) [43], [44]. 
SARS-CoV-2 genome encodes 27 proteins, including 
capsid (S) and envelope (N). The S-protein binds the 
angiotensin-converting enzyme 2 (ACE-2) receptor, 
which is widespread in many human tissues (including 
the lungs and gut) and can indirectly modulate nutrient 
transport to the intestine, reduce the bioavailability of 
vitamins and amino acids essential for the production 
of antibodies and immune regulation in general [45]. 
Clinically, SARS-CoV-2 is reported to cause respiratory 
and gastrointestinal tract symptoms. Although scientists 
around the world work hard and respond rapidly in 
developing a new vaccine or antiviral medication for 
SARS-2, no COVID-19 vaccine or new effective antiviral 
medicines are approved yet. In such circumstances, 
the most reliable and recommended strategy to control 
viral infections is prevention.
In this review, we sought to elucidate the 
mechanisms through which the probiotics exert 
their antiviral and preventive potential as well as the 
possibility of using them to improve the COVID-19 
patient’s health.
Possible Antiviral Mechanisms of 
Probiotics
The probiotics’ antiviral effects may exert 
by several mechanisms, including the production of 
antiviral inhibitory substances, direct interaction with 
viruses, or by stimulating the immune system [46]. 
These proposed mechanisms are summarized below.
Production of Viral Inhibitory Substances
A wide range of antimicrobial compounds 
is produced by probiotics such as organic 
acids, bacteriocins, hydrogen peroxide (H2O2), 
exopolysaccharides (EPS), and diacetyl. These agents 
lead to control other microbial growth [47].
Organic acids
The important and characterized antimicrobial 
compounds produced by LAB are acetic, lactic acid, 
and formic acid [48]. The major end-product of sugar 
fermentation by LAB is lactic acid which used to inhibit 
microbial growth by stress resultant from the low pH, 
which, in turn, makes the environment unfavorable 
for some pathogenic and spoilage microbial 
growth [49], [50]. The microbial inhibitory effects of 
organic acids are mainly caused by their dissociated 
forms, which, by changing the environment into acidic, 
Table 1: Some major probiotic microorganisms
Microorganism Genera Probiotic strains References
Bacteria Lactobacillus L. acidophilus [9], [10], [11], [12], [13], 
[14], [15], [16]L. amylovorus
L. brevis
L. casei
L. crispatus
L. curvatus
L. delbrueckii subsp. 
bulgaricus
L. fermentum
L. gallinarum
L. gasseri
L. johnsonii
L. paracasei
L. plantarum
L. reuteri
L. rhamnosus
L. salivarius
Bifidobacterium B. adolescentis [17], [18], [19], [20], [21], 
[22]B. animalis
B. bifidum
B. breve
B. infantis
B. longum
B. thermophilum
Enterococcus E. faecalis [23], [24]
E. faecium
Lactococcus L. lactis [25], [26]
Leuconostoc L. mesenteroides [27]
Pediococcus P. acidilactici [28]
Sporolactobacillus S. inulinus [29]
Streptococcus S. thermophilus [30]
Bacillus B. cereus [31], [32]
B. clausii
B. pumilus
B. subtilis
Escherichia E. coli Nissle 1917 [33], [34]
Propionibacterium P. freudenreichii [35]
Yeast Saccharomyces S. cerevisiae [36], [37]
S. boulardii
Figure 1: Probiotics’ beneficial properties to human health [5]
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interfere with essential metabolic functions [51], [52]. 
The acidic pH has been reported inactivates human 
immunodeficiency virus (HIV) and herpes simplex virus 
2 (HSV-2) [53], [54]. Such low pH may also participate 
in alleviating SARS-CoV-2 infectivity.
Bacteriocins
Bacteriocins are extracellular, low-molecular-
weight proteins that can inhibit the microbial growth 
of various pathogens with distinct bacteriostatic and 
bactericidal effects [47], [55]. The majority of bacteriocins 
are heat stable and sensitive to certain proteolytic 
enzymes [56]. Many bacteriocins have accordingly 
been characterized and purified from LAB and used 
for a variety of industrial and biomedical applications 
such as food and biopreservation technology, cancer 
therapy, antimicrobials, and for maintaining human 
health [57]. Bacteriocins of LAB have some pivotal 
properties that gain considerable attention, such as 
(a) being GRAS, (b) non-toxic, (c) protease-inactivated 
with a slight effect on the gut microflora, (d) can tolerate 
pH and temperature ranges, (e) having the ability to 
inhibit many food spoilage bacteria and food-borne 
pathogens, (f) having bactericidal potential, and (g) 
they are usually plasmid-encoded [58].
In the past two decades, bacteriocins have 
been reported to have antiviral properties [59]. They 
can bind, at the cellular level, to the cell surface 
receptors [60]. This, in turn, could reduce the cytopathic 
effects and intracellular RNA of the virus at a pre-
incubation condition [61]. Furthermore, bacteriocins 
and bacteriocin-like substances can interfere with 
the enzymatic reactions that are important for viral 
infection [62]. Wachsman et al. have proven the 
antiviral effect of entertain, a bacteriocin, against 
strains of HSV-1 and HSV-2 by inhibiting late stages 
of replication and effect on intracellular replication of 
the virus. Lactobacillus delbrueckii subsp. bulgaricus 
1043 bacteriocin also has a virucidal effect on 
influenza virus [63]. Moreover, the virucidal effect of the 
bacteriocin subtilosin, produced by probiotic Bacillus 
amyloliquefaciens has also been reported against 
HSV and influenza virus [40], [64]. In this context, 
bacteriocins produced by probiotics may also have 
such antiviral activities against SARS-CoV-2.
Hydrogen peroxide
H2O2 is a compound with high reactivity at 
high concentrations and quite toxic to the biological 
systems [65]. In addition, H2O2 represents a strong 
oxidizing agent that has been shown to damage cellular 
membranes, DNA, and bacterial proteins [66] and 
have an inhibitory or lethal effect on microorganisms, 
depending on certain factors including concentration, 
temperature, pH, and other environmental factors [67]. 
LAB can produce H2O2 when grown in the presence 
of oxygen through electron-transporting by different 
mechanisms involving flavin [68] and because they 
are catalase-negative, H2O2 can accumulate to higher 
concentration [50]. The induction of stress proteins 
allows LAB to tolerate higher concentrations than 
the other types of bacteria [69]. Although H2O2 and 
superoxide radical (O2−) are strong oxidant species and 
can increase the reactive oxygen species that lead to 
oxidative stress [70], a recent study by Singh et al. has 
revealed that H2O2 production by Lactobacillus johnsonii 
could promote epithelial restoration during colitis [71].
In regards to antiviral activities, H2O2, 
superoxide, and hydroxyl radicals are all suspected 
for inactivating pathogenic viruses [72]. A previous 
study has also shown that H2O2 has a significant 
anti-influenza virus activity [73]. Typically, H2O2 from 
Lactobacillus has a microbicidal effect in the vagina to 
protect the female genital tract from microbial infection. 
It also showed notable activities against type-1 and 
type-2 HIV [72], [74].
Exopolysaccharides
Polysaccharides are polymers composed of 
20 to 107 units of monosaccharides. They range from 
linear to highly branched structures [75]. However, EPS 
are long-chain biological polysaccharides produced 
by microorganisms [76]. It was proven that EPS have 
important biological activities such as antibiofilm, 
antitumor, antioxidant, and immunomodulatory 
effects [77]. EPS from the probiotic Lactobacillus 
plantarum strain N4 (Lp) have been shown to have 
an inhibitor effect on the transmissible gastroenteritis 
virus [77]. Furthermore, Callahan et al. [78] reported that 
EPS could block HIV viral entry. Such EPS may also 
have a preventive or inhibitory role against SARS-CoV-2.
Direct virus-probiotic interaction
Inactivation of viruses by LAB could also occur 
through adsorption or trapping mechanism [46]. In 
this mechanism, the interaction between bacteria and 
viruses is a principal to exhibit the antiviral effect of 
probiotics [79]. Conti et al. (2009) have reported that 
Lactobacillus isolated from vagina have a protective 
effect against HSV through the adhesive ability of 
bacteria to reduce the absorption of the virus. Bacterial 
cells may directly interact with viral particles and lead 
to trapping them or competition for cell membrane 
receptors [62]. A previous study stated that the probiotics 
trap vesicular stomatitis virus (Indiana vesiculovirus) 
through interaction between Lactobacillus cells and the 
envelope of the virus directly [80]. Similarly, Mousavi 
et al. [81] reported the mechanisms for the antiviral effect 
of L. crispatus toward HSV-2 and concluded that these 
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mechanisms include (a) formation of micro-colonies in 
the cell surface, cause blocking to the receptors and 
effect on the entry of virus into the cells and (b) trapping 
of viral particles by L. crispatus that interact directly 
with an envelope of the virus. Furthermore, L. gasseri 
inhibited HSV-2 through the trapping mechanism [82]. 
Furthermore, Wang et al. (2013) reported the inhibition 
of influenza viruses by Enterococcus faecium through 
direct interaction. However, such mechanisms may 
cease SARS-CoV-2 infection or decrease viral load 
which is a possible factor in the severity of the disease.
Stimulation of immune system
Lactobacilli have distinct antimicrobial and 
antiviral activities that play an effective regulator to 
the immune system [83]. Furthermore, they stimulate 
specific and non-specific responses, including the 
activation of natural killer (NK) cells, enhancement of 
the phagocytic activity of peripheral blood leukocytes, 
regulatory T cells, and interleukin-10. In this regard, 
the stimulation of nonspecific secretory and specific 
antibody responses to rotavirus has been recorded [84]. 
Recent work by Arena et al. (2018) has proven that 
probiotics can exert modulatory effects of the immune 
system by enhancing the immune defense against 
viruses such as induction of interleukins, T-helper cells, 
macrophages, NK cells, and immunoglobulins.
Several studies have evaluated the effect of 
some immunobiotics against enteric viruses, respiratory 
viruses, and pathogenic bacteria [85]. In 2010, the 
administration of L. pentosus to mice showed antiviral 
potential by activation of lung NK cells and decreased 
allergic reaction [86]. Heat-killed Lactobacillus 
rhamnosus strains administration has also exhibited 
IFN-α stimulation in respiratory syncytial virus (RSV) 
infection and decrease a viral load in mice lungs [87]. 
Moreover, Kawashima et al. (2011) have demonstrated 
that innate and adaptive immune systems are triggered 
by the probiotic strain, L. plantarum, isolated from 
traditional Japanese fermented food. In addition to its 
strong IL-12-inducing activity and IgA-inducing activity, 
viable L. plantarum has a high digestive juice resistance, 
leading to improved Th1 immune response and 
preventative activity against influenza virus infection. 
Too, reduction of H1N1 infection in mice by Lactobacillus 
fermentum has also been documented through the 
same mechanisms [88], [89]. Likewise, Bifidobacterium 
longum showed an anti-H1N1 activity by decreasing the 
pro-inflammatory cytokines [90]. Finally, enhancing the 
immune responses using probiotics’ supplementation is 
a well-documented point; however, it may also be an 
effective way to alleviate COVID-19.
Probiotics and Enteric Viral Infections
The rotavirus, norovirus, adenovirus, and 
astrovirus are the most common viruses that cause 
gastroenteritis. The preventive role of probiotics against 
common types of viral enteritis is discussed below: 
Rotavirus infection
The rotavirus infection is commonly responsible 
for diarrheal disease among children under 5 years of 
age, particularly in developing countries. Rotavirus 
infection is also associated with other symptoms such 
as vomiting, fever, and dehydration which can lead to 
death [91], [92]. In 2006, the US-FDA approved two oral 
live vaccines (RotaTeq and Rotarix) to prevent rotavirus 
infection in infants [93]. However, the rates of morbidity 
and mortality are still high [91]. In such circumstances, 
probiotics may consider promising cheap and safe 
preventive alternatives [94] to be administered to 
patients.
Many researchers have studied the preventive 
role of certain probiotics against rotavirus, such as 
Bifidobacterium and Lactobacillus affirmed their role 
in antagonizing rotaviruses [95]. Erdoğan et al. [96] 
have reported that the treatment of acute rotavirus 
gastroenteritis with Bifidobacterium lactis B94 and oral 
rehydration could significantly reduce the diarrheal 
period in children aged from 5 months to 5 years old. 
Later, in 2017, Park et al. [97] reach similar results 
after administering B. longum BORI and L. acidophilus 
AD031 to infants infected with rotavirus. A more recent 
study has proven that specific probiotic strains such 
as Lactobacillus salivarius PS2, L. acidophilus NCFM, 
Bifidobacterium breve M-16V, and Lactobacillus 
helveticus R0052 have the ability to reduce the severity 
of rotavirus infection [98].
Supporting the theory that probiotics can 
stimulate the host’s immune system, Sindhu et al. [99] 
have mentioned that the consumption of L. rhamnosus 
(LGG) can modulate both innate and adaptive immune 
system’s responses by increasing levels of serum 
IgG during infection with rotavirus. On the other 
hand, Fernandez-Duarte et al. [100] suggested that 
B. adolescentis and L. casei could block rotavirus 
adherence to the MA104 cells. While, a recent study 
indicated that non-protein components with low-
molecular-weight derived from B. longum BORI act as 
anti-rotaviral substances [101]; however, more studies 
are required to specify active compound to completely 
elucidate the underlying mechanism of action.
Noroviruses infection
Human norovirus can also cause gastroenteritis 
and generally lasts for 2–3 days and accompanied by 
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vomiting, nausea, and diarrhea [102]. Infants, elderly, 
and immunocompromised patients are the risk groups. 
Although acute diarrhea is generally self-limiting 
and may disappear within a few days [103], [104], 
dehydration in toddlers and young infants remains the 
major risk factor.
Developing vaccines and antiviral drugs against 
human norovirus are still under experiments [105]. 
Studies indicated that probiotics might act as adsorbents 
for P particle, a nano-scale sized particle in norovirus 
capsid and critical for the host’s immune response 
and receptor binding [106]. For example, Enterobacter 
cloacae which are a commensal bacterium could bind 
to human norovirus through surface histo-blood group 
antigen and inhibit virus infectivity when tested in 
pigs [107], [108]. Another study showed that P particle 
attachment to epithelial cells could be inhibited by the 
presence of L. casei BL23 and Escherichia coli Nissle 
1917 [109]. Accordingly, and to avoid developing severe 
forms of SARS-CoV-2, enhancing a healthy diet with 
probiotics may represent a good strategy.
Probiotics and Respiratory Viral 
Infections
While many researchers have concentrated on 
the use of probiotics to treat or prevent intestinal infections, 
recent research has focused on the effectiveness 
of probiotics on humans against respiratory viral 
infections [110], which are a serious cause of morbidity 
and mortality around the world [111]. The causative 
agents of respiratory viral infections in humans are 
over two hundred different types of pathogenic viruses, 
including RSV, human rhinoviruses (common cold), 
human enteroviruses, influenza viruses, adenoviruses, 
parainfluenza viruses, and coronaviruses. Symptoms 
of these infections vary from mild respiratory symptoms 
to severe diseases [112], [113], [114], [115]. Below, 
evidence-based probiotics’ effects against common 
infections are highlighted below:
RSV infection
One of the most common respiratory 
viruses that almost all children are infected with 
by the age of 2 years is RSV. The symptoms can 
vary from mild symptoms to severe infection of the 
lower respiratory tract, bronchiolitis, and pneumonia 
with an increasing risk of developing asthma 
and persistent wheezing [116], [117]. Elderly and 
immunocompromised individuals are most at risk to be 
infected with RSV [118], [119]. No RSV vaccine has 
been approved so far, and specific antiviral medicines 
against RSV are still limited. Several probiotics 
are therefore proposed to prevent RSV infection 
as prophylactic or antiviral agents. For example, 
Tomosada et al. (2013) have found that TLR3/RIG-I 
antiviral respiratory immune response is modulated by 
intranasal administration of two different commensal 
strains of L. rhamnosus (L. rhamnosus CRL1505 and 
L. rhamnosus CRL1506) and increased infant mice 
resistance to RSV in comparison with a control group. 
In addition, recent research has shown that the RSV 
titer in the lungs can be significantly reduced with no 
weight loss in mice after viral infection when L. gasseri 
(LG2055) is administered orally [41].
Human rhinoviruses (HRV)
Rhinoviruses are the leading causes of common 
cold in humans [120]. Severe symptoms typically 
include irritation, pneumonia, bronchiolitis, asthma, 
and chronic obstructive pulmonary disease [121]. 
There is currently no approved antiviral treatment or 
vaccine for HRV infection. However, research articles 
have documented that various probiotics could reduce 
the risk of HRV disease. In a preterm population, the 
incidence of HRV infection was reduced significantly 
during the 1st year of life through using polydextrose 
and L. rhamnosus [122]. Kumpu et al. [123] found that 
receiving L. rhamnosus GG (live or heat-inactivated) 
decreased the incidence and severity of common cold 
symptoms caused by rhinoviruses. However, the dose 
of probiotic bacterial strains, side effects, and accurate 
mechanism against HRV is inadequately reported and 
needs further investigation [124], [125].
Influenza virus infection
Another viral agent responsible for thousands 
of human and animal deaths annually is the influenza 
virus. Influenza viruses are a group of RNA viruses, 
which belong to the family Orthomyxoviridae. There 
are four types of influenza viruses A, B, C, and D. 
Mainly, humans are infected with type A and B [126]. 
Influenza A viruses are responsible for several 
pandemic outbreaks worldwide [127]. Although the 
vaccine is available but with new viral strains evolving 
rapidly and variations between circulating viruses and 
vaccines created, the efficiency of the influenza virus 
vaccine decreases [128], [129]. Therefore, the efforts 
rely on the use of probiotics to reinforce and improve 
the host’s immune system against viral infection. 
The use of yogurt fermented by L. delbrueckii 
ssp. bulgaricus OLL1073R-1 (R-1) might prevent 
infection caused by respiratory or influenza viruses 
through polysaccharides secretion, which improves 
immune system’s functions and activates the NK 
cells [130], [131]. In a mouse model, L. acidophilus 
can regulate NK T-cells and prevent influenza virus 
infection [132]. Furthermore, the B. bifidum’s effect 
on improving immune response to the influenza virus 
in a recent study on BALB/c mice infected with lethal 
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influenza A (H1N1) has been evaluated by Mahooti 
et al. [133]. Furthermore, findings revealed a strong 
induction of both humoral and cellular immunity, drop 
in the level of IL-6, and increased survival rate in mice 
receiving Bifidobacterium than those of the control 
group.
Adenoviruses infection
Adenoviruses represent group of Rowavirales 
that belong to the non-enveloped double-stranded 
linear DNA viruses. Adenoviruses can cause 
various clinical syndromes in humans in addition to 
keratoconjunctivitis, including gastrointestinal and 
urogenital infections [134]. Various antiviral drugs such 
as ribavirin, ganciclovir, and cidofovir have shown 
variable activities against severe human adenovirus 
infections especially in immunocompromised organ 
transplant recipients. However, the efficiency of these 
drugs is limited to the ability of the virus to develop 
resistant strains in addition to their side effects [135]. 
Therefore, it is safer to stimulate the immune system 
and increase resistance to adenovirus infections 
through probiotics and their metabolic products [136]. 
In-vitro MTT assay against human adenovirus type 
5 was used to examine the cytotoxicity of six EPSs 
produced by various LAB. The results showed that EPS 
26a produced by Lactobacillus sp. have a significant 
antiviral activity through the formation of non-infectious 
virus progeny [137].
Probiotics and COVID-19
In response to the emerging threat posed by 
SARS-CoV-2, the WHO announced a Public Health 
Emergency of International Concern a pandemic on 
March 11, 2020. Infection with SARS-CoV-2 causes 
coronavirus disease 19 (COVID-19), which has been 
characterized by fever, respiratory, and gastrointestinal 
symptoms, along with other less common 
symptoms [138]. No vaccine or antiviral drug for SARS-
CoV-2 has been yet approved. However, faced with this 
pandemic, new answers and ways of addressing these 
problems are needed.
Strengthening the immune system is well-
known to be an effective and successful way for a 
healthy lifestyle. This, in turn, oriented attention to the 
pivotal role of a healthy immune system to face SARS-
CoV-2 infection [139]. Open literature search revealed 
that immune system function is largely improved by 
a healthy diet. Accordingly, a diversified diet with a 
broad nutrient profile may prevent and even reduce the 
vulnerability during COVID-19.
Adjuvants against COVID-19 could be healthy 
food choices, micronutrients, bioactive compounds, and 
probiotics [140]. In particular, the potential benefits of 
probiotics in other coronavirus strains were thoroughly 
documented [141]. Some probiotics may also play a 
positive role in the treatment of COVID-19 patients due 
to their antiviral activity, ability to modulate inflammation, 
restore gut microbiome, ready availability, generally 
safe, inexpensive, and easily administered [142]. There 
are no guidelines on strain, dose, and duration of the 
probiotics consuming yet. However, Lactobacillus and 
Bifidobacterium can be safely used in different clinical 
situations.
A recent study by Aanouz et al. (2020) [143] 
on computational and molecular dynamics obviously 
demonstrates the antiviral activity of plantaricins, a 
bacteriocin, which blocks viral entry by binding with 
RdRp, RBD, and ACE2 through multiple mechanistic 
approaches by metabolic product of L. plantarum. 
Blocking the main structural protein S is critical and can 
be one of the best targets since it plays a key role in 
the life cycle of SARS-CoV-2. Moreover, Anwar et al. 
(2020) [144] have suggested that plantaricin metabolites 
may be a preventive option before the latest antiviral 
medication specific to COVID-19 has been discovered. 
Other studies are being carried out across the globe to 
decide whether modifying the gut microbiota through the 
diet will contribute to our COVID-19 care, and in recent 
times, Baud et al. (2020) [145] have suggested certain 
probiotic strains that are evidence-based and that are 
important in reducing the pandemic burden. Apart 
from boosting the immune system, specific therapeutic 
strategies may be advised for the prevention of cytokine 
storm such as the use of probiotics for patients with 
gastrointestinal symptoms linked to COVID-19 and 
those with milder systemic symptoms [146].
Different patients’ responses to infection may 
depend on variations in the composition of their microbiota 
and correction with probiotics may help to minimize the 
need for intensive care [147]. Dhar and Mohanty (2020) 
have identified the potential role of intestinal microbiota 
in determining better immune and respiratory function in 
such patients [148]. Too, number of authors discussed 
the idea of significant positive modulation of respiratory 
function by probiotics/synbiotics supplementation, 
starting from previous studies on the close associations 
between gut microbiota and lung function. In general, 
that finding indicates that probiotics are essential and 
useful supplements to patients and confirm the role of 
our microbiota in sustaining and eventually restoring a 
healthy quality of life.
For better understanding, the presented 
knowledge must be more deeply validated before they 
can be implemented in standard protocols for COVID-
19 patients, assess also the true impact of SARS-
CoV-2 on gut microbiota, and also take into account the 
possible role of gut virobiota, which seems to have a 
specific role in the homeostasis of gut microbiota [149]. 
Moreover, interactions between SARS-CoV-2 and the 
gut microbiome and resident virobiota could influence 
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the ability of this new coronavirus to infect and 
disseminate the intestinal cells more easily and explain 
how probiotics could have a COVID-19 resistance [150].
In addition to their benefits to humans, 
probiotics may also participate in certain clinical 
presentations related to life-threatening outcomes 
such as bloodstream infections [151], [152]. However, 
neither mortality nor adverse health complications were 
ascribed to the clinical use of probiotics. Furthermore, 
additional studies are demanded to better understand 
their safety, behavior in the food matrix, and their 
survival and colonization in the gastrointestinal tract 
using expressly designed in vivo models.
Conclusions
With no approved vaccine or antiviral drugs for 
some viral disease, including COVID-19, establishing 
effective means to protect humans from viral infections 
still a bit challenging. Of the safest, affordable, and easy 
to consume, agents are probiotics. Enhancing the host 
immune system with probiotics is widely studied. They 
were known with their multifunctional effects, which can 
act as adjunctive therapy for the prophylaxis of a large 
number of viral infections. Finally, research needs to 
progress to establish probiotic scientific guidelines for 
the prevention and/or treatment of COVID-19.
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